Literature DB >> 2874413

Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies.

S Chiba, T Yokoyama, S Nakata, Y Morita, T Urasawa, K Taniguchi, S Urasawa, T Nakao.   

Abstract

To assess serotype specificity of immune resistance to rotavirus gastroenteritis, the relation between pre-existing neutralising antibodies to homotypic and heterotypic rotaviruses and protection against infection or clinical illness was investigated. The subjects were 44 orphans exposed once or twice to consecutive outbreaks of gastroenteritis due to type 3 rotavirus in an orphanage in Sapporo. Sera were collected throughout these outbreaks and the serum levels of neutralising antibodies against four different serotypes of group A human rotavirus were measured before and after the outbreaks. Protection against rotavirus gastroenteritis seemed to be serotype specific and to be related to levels of antibody against homotypic virus. A neutralising antibody level of 1/128 or greater seemed to be protective. The protective effect was of short duration, which was probably the explanation for recurrent attacks of gastroenteritis due to a rotavirus of the same serotype. Seroconversions or concomitant antibody responses to type 1 or 4 rotavirus in most children with type 3 rotavirus infection suggested that immunity to heterotypic virus can be induced by a rotavirus vaccine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874413     DOI: 10.1016/s0140-6736(86)92133-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  67 in total

1.  Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995.

Authors:  L E Unicomb; G Podder; J R Gentsch; P A Woods; K Z Hasan; A S Faruque; M J Albert; R I Glass
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

2.  Serotype variation of group A rotaviruses over nine winter epidemics in southeastern New England.

Authors:  R E Begue; P H Dennehy; J Huang; P Martin
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

3.  Rotavirus-specific T-cell responses in young prospectively followed-up children.

Authors:  M Mäkelä; J Marttila; O Simell; J Ilonen
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

4.  Rotavirus virus-like particles administered mucosally induce protective immunity.

Authors:  C M O'Neal; S E Crawford; M K Estes; M E Conner
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

6.  Subgroup and serotype distributions of human, bovine, and porcine rotavirus in Thailand.

Authors:  Y Pongsuwanne; K Taniguchi; M Choonthanom; M Chiwakul; T Susansook; S Saguanwongse; C Jayavasu; S Urasawa
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

7.  Prospective study of community-acquired rotavirus infection.

Authors:  B J Zheng; S K Lo; J S Tam; M Lo; C Y Yeung; M H Ng
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

8.  Temporal and geographical distributions of human rotavirus serotypes, 1983 to 1988.

Authors:  G M Beards; U Desselberger; T H Flewett
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

Review 9.  Rotavirus vaccines: an overview.

Authors:  Penelope H Dennehy
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

10.  Assessment of the epidemic potential of a new strain of rotavirus associated with the novel G9 serotype which caused an outbreak in the United States for the first time in the 1995-1996 season.

Authors:  H Fred Clark; Diane A Lawley; Alyssa Schaffer; Janice M Patacsil; Amy E Marcello; Roger I Glass; Vivek Jain; Jon Gentsch
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.